 colorectal cancer ( crc ) is the third most common cause of cancer - related deaths with treatment of advanced and metastatic crc ( mcrc ) remaining palliative at best.1 the epidermal growth factor receptor ( egfr ) has been identified as a therapeutic target for a multitude of malignancies , including mcrc . 
 ligand - binding to egfr results in the subsequent activation of multiple signal transduction pathways including the pi3k / akt and ras / raf / mapk pathways , which are vital for cell growth and survival.2 constitutive activation of these signaling pathways leads to deregulated cellular proliferation , malignant progression , and invasion.3 
Disclosure of Potential Conflicts of Interest